This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Rite Aid (RAD) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Rite Aid (RAD) closed at $8.81 in the latest trading session, marking a -0.79% move from the prior day.
Rite Aid (RAD) Falls Despite Narrower-Than-Expected Q4 Loss
by Zacks Equity Research
Rite Aid (RAD) posts narrower-than-expected loss in fourth-quarter fiscal 2019. Moreover, it issues a soft outlook for fiscal 2020.
Rite Aid (RAD) Picks 1-for-20 Reverse Stock Split Ratio
by Zacks Equity Research
Rite Aid (RAD) approves a 1-for-20 reverse stock split to regain compliance for NYSE listing rules. This will reduce the company's outstanding shares to 54 million.
Rite Aid (RAD) to Post Q4 Earnings: What's in the Offing?
by Zacks Equity Research
Rite Aid's (RAD) results gain from efforts to leverage retail pharmacies and EnvisionRxOptions PBM as well as health and wellness offerings. However, soft outlook for fiscal 2019 concerns investors.
Rite Aid (RAD) in Focus: Stock Moves 6.1% Higher
by Zacks Equity Research
Rite Aid (RAD) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
CVS Health Stock Jumps on Bullish Coverage: Time to Buy?
by Benjamin Rains
Shares of CVS Health (CVS) surged over 4% through mid-afternoon trading Wednesday on the back of a bullish call from Bernstein analysts. The drugstore chain is also coming off a stronger-than-expected fourth quarter. So, is now the time to buy CVS stock?
Rite Aid (RAD) Plans 400 Job Cuts, Stock Up on Restructuring
by Zacks Equity Research
Rite Aid (RAD) announces leadership transition and organizational revamping in a bid to better align its operations and minimize costs.
January Retail Sales Strong Despite Shutdown: ETF & Stock Bets
by Sanghamitra Saha
Retail sales jumped in January, putting these stocks and ETFs in focus.
Implied Volatility Surging for Rite Aid (RAD) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Rite Aid (RAD) stock based on the movements in the options market lately.
CVS Health Stock Pops Before Q4 Earnings: What to Expect
by Benjamin Rains
Let's see what to expect from CVS' fourth-quarter financial results that are due out before the opening bell Wednesday.
What to Expect from CVS Health's Q4 Earnings, Revenue & Comps
by Benjamin Rains
Shares of CVS Health (CVS) have popped 4% in the last month and jumped 1.16% during regular trading Wednesday. But does this signal that investors expect good things from the pharmacy power's Q4 financial results that are due out before the opening bell on February 20?
Can Rite Aid's (RAD) Reverse Stock Split Plan Aid Stock?
by Zacks Equity Research
Rite Aid (RAD) plans a reverse stock split to lift the stock price and regain compliance under NYSE listing rules.
Is the Options Market Predicting a Spike in Rite Aid (RAD) Stock?
by Zacks Equity Research
Investors need to pay close attention to Rite Aid (RAD) stock based on the movements in the options market lately.
Rite Aid (RAD) Up 14.2% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Rite Aid (RAD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Rite Aid (RAD) in Focus: Stock Moves 6.8% Higher
by Zacks Equity Research
Rite Aid (RAD) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
Rite Aid (RAD) Stock Up on Q3 Earnings Beat, FY19 View Down
by Zacks Equity Research
Rite Aid's (RAD) top and bottom lines improve year over year. Also, earnings came ahead of the Zacks Consensus Estimate but sales lagged the same.
Rite Aid (RAD) Tops Q3 Earnings Estimates
by Zacks Equity Research
Rite Aid (RAD) delivered earnings and revenue surprises of 150.00% and -0.62%, respectively, for the quarter ended November 2018. Do the numbers hold clues to what lies ahead for the stock?
Implied Volatility Surging for Rite Aid (RAD) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Rite Aid (RAD) stock based on the movements in the options market lately.
Factors Likely to Shape Rite Aid's (RAD) Earnings in Q3
by Zacks Equity Research
Unfavorable trends in the generic drug market affect Rite Aid (RAD). However, it is aiming at capitalizing on its growth potential.
Implied Volatility Surging for Rite Aid (RAD) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Rite Aid (RAD) stock based on the movements in the options market lately.
What to Expect from CVS Health's Q3 Earnings
by Benjamin Rains
Let's see what to expect from CVS before the opening bell Tuesday.
Should You Buy CVS Stock Ahead of Q3 Earnings?
by Benjamin Rains
Let's see if investors should think about buying CVS stock ahead of its Q3 financial results.
Why Is Rite Aid (RAD) Down 16% Since Last Earnings Report?
by Zacks Equity Research
Rite Aid (RAD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Walgreens Boots (WBA) Stock Looks Like A Cheap, Solid Buy Right Now
by Benjamin Rains
Shares of Walgreens Boots Alliance (WBA) jumped roughly 1.6% Monday as investors continue to dive in after it posted impressive fiscal fourth-quarter results late last week. Looking ahead, the pharmaceutical giant looks poised for strong growth and WBA stock seems like it might be worth buying right now.
Should You Buy Walgreens Boots (WBA) Stock Ahead of Q4 Earnings?
by Benjamin Rains
Walgreens Boots Alliance (WBA) shares have surged 17% in the last three months to outpace the S&P 500's roughly 7% climb as fears that Amazon's (AMZN) pharmaceutical push would doom the pharmacy giant prove overblown. Now the question is should investors consider buying WBA stock ahead of its Q4 earnings release on October 11?